TPST übertreffen die 21 der letzten 37Schätzungen.
57%
Nächster Bericht
Datum des nächsten Berichts
25. März 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
-$3.59
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
+354.43%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
-10.92%
Tempest Therapeutics, Inc. Common Stock earnings per share and revenue
On 05. Nov. 2025, TPST reported earnings of -0.79 USD per share (EPS) for Q3 25, beating the estimate of -3.33 USD, resulting in a 76.31% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +9.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -3.59 USD, with revenue projected to reach -- USD, implying an increase of 354.43% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26. Dez. 2025 For Q4 25
Estimate
-$0.49
Aktuell
-
Überraschung
-
FAQ
What were Tempest Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Tempest Therapeutics, Inc. Common Stock reported EPS of -$0.79, beating estimates by 76.31%, and revenue of $0.00, 0% as expectations.
How did the market react to Tempest Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 9.1%, changed from $9.12 before the earnings release to $9.95 the day after.
When is Tempest Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 25. März 2026.
What are the forecasts for Tempest Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Tempest Therapeutics, Inc. Common Stock is expected to report EPS of -$3.59 and revenue of -- for Q4 2025.